Publications by authors named "Cora N Sternberg"

100Publications

Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.

Transl Oncol 2020 Nov 12;14(1):100944. Epub 2020 Nov 12.

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States; Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine and NewYork Presbyterian, New York, NY, United States. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.tranon.2020.100944DOI Listing
November 2020

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.

N Engl J Med 2020 09 18;383(13):1218-1230. Epub 2020 Sep 18.

From Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St. Bartholomew's Hospital, London (T.P.); Sungkyunkwan University Samsung Medical Center, Seoul, South Korea (S.H.P.); Centre Jean Bernard Clinique Victor Hugo, Le Mans (E.V.), and Gustave Roussy, INSERM Unité 981, Université Paris-Saclay, Villejuif (Y.L.) - both in France; the Medical Oncology Unit, Azienda Ospedaliera S. Maria, Terni (C.C.), and Pfizer, Milan (C.F., A.P.) - both in Italy; the Department of Medical Oncology, Hospital Universitario Virgen del Rocío, Seville, Spain (B.P.V.); the Department of Clinical Medicine, Macquarie University, Sydney (H.G.); the Division of Oncology, Department of Medicine, University General Hospital of Patras, Patras, Greece (H.K.); the Institute for Oncology and Radiology of Serbia, Belgrade (S.R.); the Department of Medical Oncology, Algemeen Ziekenhuis Klina, Brasschaat, Belgium (W.D.); Patient Area Pelvic Cancer, Theme Cancer, Karolinska University Hospital, and the Department of Oncology-Pathology, Karolinska Institute, Solna, Sweden (A.U.); Princess Margaret Cancer Centre, University Health Network, Toronto (S.S.S.); the Department of Urology, Yamagata University Faculty of Medicine, Yamagata, Japan (N.T.); the State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia (E.K.); the Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York (C.N.S.); the Department of Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston (J.B.), and Pfizer, Cambridge (R.L., J.W.) - both in Massachusetts; Inova Schar Cancer Institute, Fairfax, VA (J.B.A.-C.); Yale Cancer Center, New Haven (D.P.P.), and Pfizer, Groton (B.H.) - both in Connecticut; Pfizer, La Jolla, CA (C.D., J.A.B.-H.); Pfizer, Porto Salvo, Portugal (N.C.); and the Department of Medicine, Division of Oncology, University of Washington, and the Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, Seattle (P.G.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2002788DOI Listing
September 2020

Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes.

Cancer Treat Rev 2020 Aug 10;88:102057. Epub 2020 Jun 10.

Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2020.102057DOI Listing
August 2020

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.

N Engl J Med 2020 06 29;382(23):2197-2206. Epub 2020 May 29.

From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa2003892DOI Listing
June 2020

Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.

Clin Genitourin Cancer 2020 08 7;18(4):284-294. Epub 2020 Jan 7.

Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.12.019DOI Listing
August 2020

Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.

Eur Urol 2020 04 27;77(4):508-547. Epub 2020 Jan 27.

University of Bern, Bern, Switzerland; Department of Medical Oncology and Haematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2020.01.012DOI Listing
April 2020

COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell Carcinoma.

Clin Genitourin Cancer 2019 12 6;17(6):425-435.e4. Epub 2019 Feb 6.

Department of Genitourinary Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.01.015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7518515PMC
December 2019

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.

N Engl J Med 2019 12 30;381(26):2506-2518. Epub 2019 Sep 30.

From the Erasmus Medical Center, Rotterdam, the Netherlands (R.W.); the Institute of Cancer Research and the Royal Marsden Hospital, London (J.B.); Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); Institut Gustave Roussy and University of Paris Sud, Villejuif (K.F.), Jean Godinot Institute and Reims Champagne-Ardenne University, Reims (J.-C.E.), Foch Hospital, Suresnes (C.T.), Hôpital d'Instruction des Armées Bégin, Saint Mandé (C.H.), and Sanofi, Europe Medical Oncology, Paris (C.G.-R.) - all in France; Institut de Recherche Clinique, Université Catholique de Louvain, Louvain, Belgium (B.T.); the Department of Urology, Asklepios Tumorzentrum Hamburg, Asklepios Klinik Altona, Hamburg (C.W.), and Studienpraxis Urologie, Nürtingen (S.F.) - both in Germany; the Medical University of Vienna, Vienna (G.K.); Alexandra Hospital, National and Kapodistrian University of Athens, Athens (A.B.); Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona (J.C.); Azienda Ospedaliera Universitaria Integrata, Verona, and Fondazione Policlinico Agostino Gemelli IRCCS, Rome - both in Italy (R.I.); Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic (B.M.); Landspitali University Hospital, Reykjavik, Iceland (Á.S.); Sanofi, Global Medical Oncology, Cambridge, MA (A.O.); and 12 de Octubre University Hospital, Madrid (D.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1911206DOI Listing
December 2019

Somatic and germline sequencing in genitourinary oncology: genetics for the clinician.

Curr Opin Urol 2019 07;29(4):315-318

Division of Hematology and Medical Oncology, Englander Institute for Precision Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000643DOI Listing
July 2019

Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer.

Authors:
Cora N Sternberg

Future Oncol 2019 May 8;15(13):1437-1457. Epub 2019 Mar 8.

Division of Medical Oncology, Weill Cornell Medical Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0940DOI Listing
May 2019

Clinical Trials Corner.

Bladder Cancer 2018 Oct 29;4(4):447-449. Epub 2018 Oct 29.

Weill Cornell Medicine, New York-Presbyterian, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BLC-189040DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218109PMC
October 2018

Enzalutamide in Castration-Resistant Prostate Cancer.

N Engl J Med 2018 10;379(14):1381

San Camillo Forlanini Hospital, Rome, Italy

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1810065DOI Listing
October 2018

Clinical Trials Corner.

Bladder Cancer 2018 Jul 30;4(3):347-350. Epub 2018 Jul 30.

Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BLC-189036DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087452PMC
July 2018

Clinical Trials Corner.

Bladder Cancer 2018 Apr 26;4(2):243-244. Epub 2018 Apr 26.

Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BLC-189033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929298PMC
April 2018

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

N Engl J Med 2018 Jun;378(26):2465-2474

From the Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (M.H.), and Astellas Pharma, Northbrook (D.P., A.K.) - both in Illinois; Institut Gustave Roussy, University of Paris Sud, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.); Herlev Hospital, Herlev, Denmark (P.R.); Carolina Urologic Research Center, Myrtle Beach, SC (N.S.); State University of Campinas (Unicamp), Campinas, Brazil (U.F.); Kiev City Clinical Hospital 3, Kiev, Ukraine (P.I.); Pfizer, San Francisco (E.D., K.M.); and the Department of Medical Oncology, San Camillo Forlanini Hospital, Rome (C.N.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1800536DOI Listing
June 2018

The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.

Cancer Treat Rev 2018 Jul 3;68:25-37. Epub 2018 May 3.

Service d'Urologie, Institut de Recherche Clinique, Université Catholique de Louvain, Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2018.04.014DOI Listing
July 2018

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Eur Urol 2019 01 16;75(1):88-99. Epub 2018 Apr 16.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA; Department of Urology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, School of Medicine, Baltimore, MD, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.03.028DOI Listing
January 2019

Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer.

J Clin Oncol 2018 06 28;36(16):1579-1587. Epub 2018 Mar 28.

David J. Vaughn, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; Joaquim Bellmunt and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA; Yves Fradet, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; Jae Lyun Lee, Asan Medical Center and University of Ulsan College of Medicine, Seoul, Republic of Korea; Lawrence Fong, University of California, San Francisco, San Francisco; David I. Quinn, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA; Nicholas J. Vogelzang, Comprehensive Cancer Centers of Nevada, Las Vegas, NV; Miguel A. Climent, Fundación Instituto Valenciano de Oncología, Valencia, Spain; Daniel P. Petrylak, Smilow Cancer Hospital, Yale University, New Haven, CT; Andrea Necchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan; Cora N. Sternberg, San Camillo and Forlanini Hospitals, Rome, Italy; Winald Gerritsen, Radboud University Medical Center, Nijmegen; Ronald de Wit, Erasmus University Medical Center Cancer Institute, Rotterdam, the Netherlands; Howard Gurney, Westmead Hospital and Macquarie University, Sydney, New South Wales, Australia; Stephane Culine, Hôpital Saint-Louis, Paris, France; Yabing Mai, Haojie Li, and Rodolfo F. Perini, Merk & Co., Inc., Kenilworth, NJ; and Dean F. Bajorin, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.76.9562
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.76.9562DOI Listing
June 2018

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.

Eur J Cancer 2018 05 20;94:87-94. Epub 2018 Mar 20.

Cambridge University Health Partners, R4 Block, Box 193, Cambridge Biomedical Campus, Hills Road, Cambridge, England, CB2 0QQ, UK. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.02.009DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6774240PMC
May 2018

Clinical Trials Corner.

Bladder Cancer 2018 Jan 20;4(1):133-136. Epub 2018 Jan 20.

Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BLC-189028DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5798534PMC
January 2018

Clinical Trials Corner.

Bladder Cancer 2017 Oct 27;3(4):315-317. Epub 2017 Oct 27.

Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BLC-179024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5676764PMC
October 2017

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.

J Clin Oncol 2017 Dec 13;35(35):3916-3923. Epub 2017 Sep 13.

Robert J. Motzer and Paul Russo, Memorial Sloan Kettering Cancer Center, New York, NY; Naomi B. Haas, University of Pennsylvania, Philadelphia, PA; Frede Donskov, Aarhus University Hospital, Aarhus, Denmark; Marine Gross-Goupil, Bordeaux University Hospital, Bordeaux, France; Sergei Varlamov, Altai Regional Cancer Center, Barnaul; Evgeny Kopyltsov, State Institution of Healthcare Regional Clinical Oncology Dispensary, Omsk, Russia; Jae Lyun Lee, University of Ulsan College of Medicine; Ho Yeong Lim, Sungkyunkwan University, Seoul, Republic of Korea; Bohuslav Melichar, Palacky University Medical School and Teaching Hospital, Olomouc; Milada Zemanova, Charles University and General University Hospital, Prague, Czech Republic; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA; Lori A. Wood, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia; M. Neil Reaume, Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; Arnulf Stenzl, University Hospital Tübingen, Tübingen; Christian Doehn, University of Lübeck Medical School and Urologikum Lübeck, Lübeck, Germany; Simon Chowdhury, Guy's and St Thomas' National Health Service Foundation/St Thomas' Hospital, London; Ray McDermott, Tallaght University Hospital and Cancer Trials Ireland, Dublin; Agnieszka Michael, University of Surrey, Guildford, United Kingdom; Weichao Bao, Marlene J. Carrasco-Alfonso, and Maurizio Voi, Novartis Oncology, East Hanover, NJ; Paola Aimone, Novartis Pharma AG, Basel, Switzerland; and Cora N. Sternberg, San Camillo Forlanini Hospital, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.73.5324DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018511PMC
December 2017

Clinical Trials Corner.

Bladder Cancer 2017 Jul 27;3(3):229-230. Epub 2017 Jul 27.

Urologic Oncology Branch, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BLC-179022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545916PMC
July 2017

The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer.

Eur Urol Focus 2016 Dec 6;2(5):480-487. Epub 2017 Jan 6.

Service d'Urologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2016.12.006DOI Listing
December 2016

Systemic chemotherapy in muscle invasive and metastatic bladder cancer: present and future.

Urologia 2017 Aug 14;84(3):130-141. Epub 2017 Jun 14.

 Department of Medical Oncology, San Camillo Forlanini Hospital, Padiglione Flajani, Rome - Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5301/uj.5000230DOI Listing
August 2017

Clinical Trials Corner.

Bladder Cancer 2017 Apr 27;3(2):141-142. Epub 2017 Apr 27.

Urologic Oncology Branch, National Cancer Institute, Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BLC-179016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5409041PMC
April 2017

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma.

N Engl J Med 2017 03 17;376(11):1015-1026. Epub 2017 Feb 17.

From Dana-Farber Cancer Institute, Boston (J.B., T.K.C.); Parc de Salut Mar, Hospital del Mar Medical Research Institute, Barcelona (J.B.), and Fundación Instituto Valenciano de Oncología, Valencia (M.A.C.) - both in Spain; Erasmus MC Cancer Institute, Rotterdam (R.W.), and Radboud University Medical Center, Nijmegen (W.G.) - both in the Netherlands; Abramson Cancer Center, University of Pennsylvania, Philadelphia (D.J.V.); Centre Hospitalier Universitaire de Québec-Université Laval, Quebec, QC, Canada (Y.F.); Asan Medical Center and University of Ulsan College of Medicine, Seoul, South Korea (J.-L.L.); the University of California, San Francisco, San Francisco (L.F.); Comprehensive Cancer Centers of Nevada, Las Vegas (N.J.V.); Smilow Cancer Hospital, Yale University, New Haven, CT (D.P.P.); Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (A.N.); Westmead Hospital and Macquarie University, Sydney (H.G.); the University of Southern California Norris Comprehensive Cancer Center and Hospital, Los Angeles (D.I.Q.); Hôpital Saint-Louis, Paris (S.C.); San Camillo and Forlanini Hospitals, Rome (C.N.S.); Merck, Kenilworth, NJ (Y.M., C.H.P., R.F.P.); and Memorial Sloan Kettering Cancer Center, New York (D.F.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1613683DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635424PMC
March 2017

Prostate cancer in 2016: Improved outcomes and precision medicine come within reach.

Nat Rev Urol 2017 Feb 4;14(2):71-72. Epub 2017 Jan 4.

Weill Cornell Medical College, Division of Medical Oncology, 525 East 68th Street, Box 403, New York 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrurol.2016.270DOI Listing
February 2017

Clinical Trials Corner.

Bladder Cancer 2016 Oct 27;2(4):469-471. Epub 2016 Oct 27.

Urologic Oncology Branch, National Cancer Institute , Bethesda, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BLC-169010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5181657PMC
October 2016

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Authors:
Christian Dittrich Michael Kosty Svetlana Jezdic Doug Pyle Rossana Berardi Jonas Bergh Nagi El-Saghir Jean-Pierre Lotz Pia Österlund Nicholas Pavlidis Gunta Purkalne Ahmad Awada Susana Banerjee Smita Bhatia Jan Bogaerts Jan Buckner Fatima Cardoso Paolo Casali Edward Chu Julia Lee Close Bertrand Coiffier Roisin Connolly Sarah Coupland Luigi De Petris Maria De Santis Elisabeth G E de Vries Don S Dizon Jennifer Duff Linda R Duska Alexandru Eniu Marc Ernstoff Enriqueta Felip Martin F Fey Jill Gilbert Nicolas Girard Andor W J M Glaudemans Priya K Gopalan Axel Grothey Stephen M Hahn Diana Hanna Christian Herold Jørn Herrstedt Krisztian Homicsko Dennie V Jones Lorenz Jost Ulrich Keilholz Saad Khan Alexander Kiss Claus-Henning Köhne Rainer Kunstfeld Heinz-Josef Lenz Stuart Lichtman Lisa Licitra Thomas Lion Saskia Litière Lifang Liu Patrick J Loehrer Merry Jennifer Markham Ben Markman Marius Mayerhoefer Johannes G Meran Olivier Michielin Elizabeth Charlotte Moser Giannis Mountzios Timothy Moynihan Torsten Nielsen Yuichiro Ohe Kjell Öberg Antonio Palumbo Fedro Alessandro Peccatori Michael Pfeilstöcker Chandrajit Raut Scot C Remick Mark Robson Piotr Rutkowski Roberto Salgado Lidia Schapira Eva Schernhammer Martin Schlumberger Hans-Joachim Schmoll Lowell Schnipper Cristiana Sessa Charles L Shapiro Julie Steele Cora N Sternberg Friedrich Stiefel Florian Strasser Roger Stupp Richard Sullivan Josep Tabernero Luzia Travado Marcel Verheij Emile Voest Everett Vokes Jamie Von Roenn Jeffrey S Weber Hans Wildiers Yosef Yarden

ESMO Open 2016 29;1(5):e000097. Epub 2016 Sep 29.

Department of General Medical Oncology , University Hospitals Leuven , Leuven , Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2016-000097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070299PMC
September 2016

Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide.

Crit Rev Oncol Hematol 2016 Oct 15;106:14-24. Epub 2016 Jul 15.

Department of Medical Oncology, San Camillo and Forlanini Hospitals, Padiglione Flajani, Circonvallazione Gianicolense 87, Rome, 00152, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2016.07.005DOI Listing
October 2016

Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial.

Authors:
Cora N Sternberg

Eur Urol 2016 06;69(6):1155-6

Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.02.022DOI Listing
June 2016

Improving Survival for Metastatic Castrate-resistant Prostate Cancer: Will Combination Therapy Help Us To Move Forward?

Authors:
Cora N Sternberg

Eur Urol 2016 11 30;70(5):722-723. Epub 2016 May 30.

Medical Oncology, San Camillo and Forlaninini Hospital, Rome, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2016.05.030DOI Listing
November 2016

Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials.

Eur J Cancer 2016 07 7;61:111-21. Epub 2016 May 7.

Molecular Therapy and Pharmacogenomic Unit, ASST di Cremona, Viale Concordia 1, 26100, Cremona, Italy; Department of Medical, Surgery and Health Sciences, University of Trieste, Piazza Ospitale 1, 34129, Trieste, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2016.04.002DOI Listing
July 2016

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.

J Clin Oncol 2016 Apr 22;34(12):1402-18. Epub 2016 Feb 22.

Howard I. Scher, Michael J. Morris, Dana E. Rathkopf, and Susan F. Slovin, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College; David Nanus, NewYork Presbyterian Weill Cornell Medical Center; Lawrence W. Schwartz, NewYork Presbyterian Columbia University Medical Center, New York, NY; Walter M. Stadler, University of Chicago Medicine, Chicago, IL; Celestina Higano and Peter S. Nelson, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA; Ethan Basch, University of North Carolina at Chapel Hill, Chapel Hill, NC; Emmanual S. Antonarakis and Michael A. Carducci, Johns Hopkins University School of Medicine, Baltimore, MD; Tomasz M. Beer, Oregon Health and Science University, Portland, OR; Paul G. Corn and Christopher Logothetis, MD Anderson Cancer Center, Houston, TX; Robert Dreicer, University of Virginia School of Medicine, Charlottesville, VA; Daniel J. George, Susan Halabi, and Andrew J. Armstrong, Duke University and Duke Cancer Institute, Durham, NC; Elisabeth I. Heath, Wayne State University Karmanos Cancer Institute, Detroit; and Maha Hussain, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Wm. Kevin Kelly, Sidney Kimmel School of Medicine at Thomas Jefferson University, Philadelphia, PA; Glenn Liu and George Wilding, University of Wisconsin Carbone Cancer Center, Madison, WI; Mark N. Stein, The Cancer Institute of New Jersey, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, NJ; Charles S. Ryan and Eric J. Small, University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Oliver Sartor, Tulane School of Medicine, New Orleans, LA; Matthew Raymond Smith, Massachusetts General Hospital Cancer Center and Harvard Medical School; Mary-Ellen Taplin and Philip W. Kantoff, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, Franc

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.2702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872347PMC
April 2016

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer.

Transl Androl Urol 2015 Jun;4(3):355-64

Department of Medical Oncology, San Camillo and Forlanini Hospitals, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2223-4683.2015.04.11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708230PMC
June 2015

Chemotherapy for Muscle-Invasive Bladder Cancer.

Curr Treat Options Oncol 2016 Jan;17(1)

Department of Medical Oncology, San Camillo Forlanini Hospital, Padiglione Flajani, Circonvallazione Gianicolense 87, Rome, 00152, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11864-015-0376-yDOI Listing
January 2016

A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up.

Ann Nucl Med 2016 Feb 27;30(2):163-8. Epub 2015 Nov 27.

Department of Nuclear Medicine, Azienda Ospedaliera San Camillo Forlanini, Circonvallazione Gianicolense No. 87, 00152, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12149-015-1044-9DOI Listing
February 2016

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Drug Des Devel Ther 2015 29;9:3325-39. Epub 2015 Jun 29.

Medical Oncology Department, San Camillo and Forlanini Hospitals, Rome, Italy.

View Article

Download full-text PDF

Source
http://www.dovepress.com/enzalutamide-for-the-treatment-of-m
Publisher Site
http://dx.doi.org/10.2147/DDDT.S69433DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492664PMC
March 2016

Future directions and targeted therapies in bladder cancer.

Hematol Oncol Clin North Am 2015 Apr 13;29(2):361-76, x. Epub 2014 Dec 13.

Department of Medical Oncology, San Camillo Forlanini Hospital, Padiglioni Flajani, 1st Floor, Circonvallazione Gianicolense 87, Rome 00152, Italy. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2014.10.008DOI Listing
April 2015